iBio, Inc. announced that a single dose of its antibody candidate IBIO-610 achieved up to 98% inhibition of active Activin E for eight weeks in obese non-human primates. When combined with semaglutide, IBIO-610 enhanced visceral and total fat loss while reducing lean mass loss by 73% compared to semaglutide alone. These results suggest IBIO-610 could offer a long-acting, fat-selective obesity treatment with potential as a standalone or complementary therapy. Full data will be presented at the 2026 European Association for the Study of Diabetes Annual Meeting in Milan.
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
